REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Clinical trials for REFRACTORY ACUTE MYELOID LEUKEMIA (AML) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE MYELOID LEUKEMIA (AML) trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE MYELOID LEUKEMIA (AML), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for AML patients: Heart-Safe drug combo enters trials
Disease control Not yet recruitingThis study tests a three-drug combination (aclarubicin, azacitidine, venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo improves remission rates. About 11…
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 12:09 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Not yet recruitingThis early-stage trial tests a new treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target a protein …
Matched conditions: REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 26, 2026 12:00 UTC